Search Results 671-680 of 19274 for Myocardium
Clinically significant (i.e., active) cardiovascular disease: cerebral vascular accident/stroke (< 6 months prior to enrollment), myocardial infarction (< 6 ...
myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) within 6 months before randomization.
... myocardial infarction, or stroke within 6 months prior to the planned first dose of tazemetostat; or ventricular cardiac arrhythmia requiring medical treatment ...
History of myocardial infarction ≤ 6 months prior to registration, or congestive heart failure requiring use of ongoing maintenance therapy for life ...
Transmural myocardial infarction within the last 6 months;; Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration ...
History of myocardial infarction, stroke, transient ischemic attack, unstable angina, coronary artery bypass surgery, or other revascularization procedures ...
Patients with a history of known coronary artery disease or a myocardial infarction within the last 12 months; Patients with a known history of serious ...
... myocardial infarction within 6 months of screening. QTcF prolongation (defined as a QTcF > 480 msec). Active, clinically significant Electrocardiogram (ECG) ...
- Myocardial infarction within 6 months prior to day 1 of treatment - Clinically significant arrhythmias or conduction block (premature atrial contractions ...
Myocardial infarction less than 6 months before start of study drug 4. Anti-arrhythmic therapy (beta blockers are permitted) 5. Any unstable ischemic ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.